Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) Sees Significant Increase in Short Interest

Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) was the recipient of a significant growth in short interest during the month of January. As of January 31st, there was short interest totalling 8,250,000 shares, a growth of 5.4% from the January 15th total of 7,830,000 shares. Currently, 22.6% of the shares of the company are short sold. Based on an average trading volume of 1,490,000 shares, the short-interest ratio is presently 5.5 days.

Institutional Investors Weigh In On Ginkgo Bioworks

Several hedge funds have recently bought and sold shares of the stock. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its position in shares of Ginkgo Bioworks by 15.9% in the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 41,995 shares of the company’s stock valued at $412,000 after buying an additional 5,746 shares in the last quarter. Shay Capital LLC bought a new stake in shares of Ginkgo Bioworks in the fourth quarter worth $223,000. Point72 Asset Management L.P. acquired a new position in Ginkgo Bioworks in the fourth quarter valued at $980,000. OMERS ADMINISTRATION Corp acquired a new position in Ginkgo Bioworks in the fourth quarter valued at $342,000. Finally, Millennium Management LLC lifted its holdings in Ginkgo Bioworks by 357.4% in the fourth quarter. Millennium Management LLC now owns 670,065 shares of the company’s stock valued at $6,580,000 after buying an additional 523,571 shares during the period. 78.63% of the stock is currently owned by institutional investors and hedge funds.

Ginkgo Bioworks Price Performance

Shares of DNA stock opened at $13.79 on Wednesday. The stock’s 50 day moving average is $11.34. The firm has a market capitalization of $792.36 million, a P/E ratio of -1.05 and a beta of 1.16. Ginkgo Bioworks has a 12-month low of $5.26 and a 12-month high of $64.40.

About Ginkgo Bioworks

Ginkgo Bioworks Holdings, Inc, together with its subsidiaries, develops platform for cell programming in the United States. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. It serves pharma and biotech, agriculture, industrial and environment, food and nutrition, consumer and technology, and government and defense industries.